Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Myocarditis and Pericarditis Related to mRNA COVID-19 Vaccination: A Case Report

Author(s): Pérez López Elena María*, Rangel Sousa Diego and Navarro Roldán Jorge

Volume 19, Issue 1, 2024

Published on: 18 April, 2023

Page: [154 - 158] Pages: 5

DOI: 10.2174/1574886318666230329123459

Price: $65

Abstract

Introduction: Reported cases after the post-commercialization phase of mRNA vaccines against COVID-19 have revealed that myocarditis and pericarditis may occur predominantly in male adolescents after the second dose of the vaccine.

Case Presentation: We report two cases of cardiac disorders associated with mRNA COVID-19 vaccination, both of them in 15 year-old males. One of the patients presented acute pericarditis and the second one presented acute myocarditis with left ventricular dysfunction at hospital discharge.

Discussion and Conclusion: Physicians should be aware with the typical manifestations of these cardiovascular events after the vaccination and report suspicious cases to pharmacovigilance agencies as soon as possible. The population should rely on the pharmacovigilance system that continues to recommend vaccination as the most effective strategy to reduce the negative consequences of the pandemic.

Keywords: COVID-19, mRNA vaccine, myocarditis, pericarditis, systolic dysfunction, pharmacovigilance system.

« Previous Next »
Graphical Abstract

[1]
U.S. Food & Drug Administration. Approval letter - SPIKEVAX. 2021. Available From: https://www.fda.gov/media/151710/download
[2]
U.S. Food & Drug Administration. Approval letter - Comirnaty. 2021. Available From: https://www.fda.gov/media/155815/download
[3]
Centers for disease control and prevention. Myocarditis and pericarditis. 2021. Available From: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/myoc arditis.html
[4]
European medicines agency. COVID-19 vaccines: Update on ongoing evaluation of myocarditis and pericarditis. 2021. Available From: https://www.ema.europa.eu/en/news/covid-19-vaccines-update-ongoing-evaluation-myocarditis-pericarditis
[5]
Misra S, Shukla AK, Jhaj R, Ahmed S, Nanda M, Chaudhary D. Agreement between WHO-UMC causality scale and the Naranjo algorithm for causality assessment of adverse drug reactions. J Family Med Prim Care 2021; 10(9): 3303-8.
[http://dx.doi.org/10.4103/jfmpc.jfmpc_831_21] [PMID: 34760748]
[6]
Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med 2020; 383(27): 2603-15.
[http://dx.doi.org/10.1056/NEJMoa2034577] [PMID: 33301246]
[7]
Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021; 384(5): 403-16.
[http://dx.doi.org/10.1056/NEJMoa2035389] [PMID: 33378609]
[8]
Saeed S, Käsk L, Rajani R, Larsen TH. Incidence, clinical presentation and management of myocarditis following mRNA-based COVID-19 vaccines: A brief report. Cardiology 2022; 147(4): 406-12.
[http://dx.doi.org/10.1159/000522216] [PMID: 35104821]
[9]
Cai C, Peng Y, Shen E, et al. A comprehensive analysis of the efficacy and safety of COVID-19 vaccines. Mol Ther 2021; 29(9): 2794-805.
[http://dx.doi.org/10.1016/j.ymthe.2021.08.001] [PMID: 34365034]
[10]
Oster ME, Shay DK, Su JR, et al. Myocarditis cases reported after mRNA-Based COVID-19 vaccination in the US from december 2020 to August 2021. JAMA 2022; 327(4): 331-40.
[http://dx.doi.org/10.1001/jama.2021.24110] [PMID: 35076665]
[11]
European Medicines Agency. Comirnaty, INN-tozinameran. Summary of product characteristics. 2021. Available From: https://www.ema.europa.eu/en/documents/product-information/comirnaty-epar-product-information_en.pdf
[12]
European Medicines Agency. Spikevax, INN-elasomeran. Summary of Product Characteristics. 2021. Available From: https://www.ema.europa.eu/en/documents/product-information/spikevax-previously-covid-19-vaccine-moderna-epar-product-information_en.pdf
[13]
Chen JH, Ikwuanusi IA, Bommu VJL, et al. COVID-19 vaccine-related myocarditis: A descriptive study of 40 case reports. Cureus 2022; 14(1): e21740.
[http://dx.doi.org/10.7759/cureus.21740] [PMID: 35251812]
[14]
Das BB, Moskowitz WB, Taylor MB, Palmer A. Myocarditis and pericarditis following mRNA COVID-19 vaccination: What do we know so far? Children 2021; 8(7): 607.
[http://dx.doi.org/10.3390/children8070607] [PMID: 34356586]
[15]
Vojdani A, Kharrazian D. Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases. Clin Immunol 2020; 217: 108480.
[http://dx.doi.org/10.1016/j.clim.2020.108480] [PMID: 32461193]
[16]
Istampoulouoglou I, Dimitriou G, Späni S, et al. Myocarditis and pericarditis in association with COVID-19 mRNA-vaccination: Cases from a regional pharmacovigilance centre. Glob Cardiol Sci Pract 2021; 2021(3): e202118.
[http://dx.doi.org/10.21542/gcsp.2021.18] [PMID: 34805376]
[17]
Dionne A, Sperotto F, Chamberlain S, et al. Association of myocarditis with BNT162b2 messenger RNA COVID-19 vaccine in a case series of children. JAMA Cardiol 2021; 6(12): 1446-50.
[http://dx.doi.org/10.1001/jamacardio.2021.3471] [PMID: 34374740]
[18]
Verma AK, Lavine KJ, Lin CY. Myocarditis after COVID-19 mRNA vaccination. N Engl J Med 2021; 385(14): 1332-4.
[http://dx.doi.org/10.1056/NEJMc2109975] [PMID: 34407340]
[19]
European Medicines Agency. Meeting highlights from the pharmacovigilance risk assessment committee (PRAC). 2021. Available From: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-29-november-2-december-2021
[20]
World Health Organization. COVID-19 subcommittee of the WHO global advisory committee on vaccine safety (GACVS): Updated guidance regarding myocarditis and pericarditis reported with COVID-19 mRNA vaccines. 2021. Available From: https://www.who.int/news/item/09-07-2021-gacvs-guidance-myocarditis-pericarditis-covid-19-mrna-vaccines
[21]
Centers for Disease Control and Prevention. Clinical Considerations: Myocarditis and pericarditis after receipt of mRNA COVID- 19 vaccines among adolescents and young adults. 2022. Available From: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html
[22]
Kornowski R, Witberg G. Acute myocarditis caused by COVID-19 disease and following COVID-19 vaccination. Open Heart 2022; 9(1): e001957.
[http://dx.doi.org/10.1136/openhrt-2021-001957] [PMID: 35264415]

Rights & Permissions Print Cite
Article Metrics
18
2
© 2024 Bentham Science Publishers | Privacy Policy